Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Novartis says lung cancer drug Zykadia gains EU approval

Written by: | no-reply@reuters.com | Dated: Friday, May 8th, 2015

Swiss drugmaker Novartis said European health regulators have approved a drug for advanced lung cancer that is intended to treat patients with a specific genetic mutation.

Zykadia, or ceritinib, is from a new class of medicines known as ALK inhibitors. It was approved in April 2014 in the United States.

It is designed for use in non-small cell lung cancer patients who have previously been treated with Pfizer’s Xalkori, another ALK inhibitor.

Between 2 and 7 percent of non-small cell lung cancer patients have the specific mutation of the ALK (anaplastic lymphoma kinase) protein for which such treatment is targeted. They are often non smokers.

 

 

(Reporting by Katharina Bart; Editing by Michael Perry)


Source: Reuters

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom